<front xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><journal-meta><journal-id journal-id-type="publisher-id">CRIPE</journal-id><journal-title-group><journal-title>Case Reports in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2090-6811</issn><issn pub-type="ppub">2090-6803</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2020/1532875</article-id><article-id pub-id-type="publisher-id">1532875</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Primary Cutaneous Nocardiosis in an Adolescent with Crohn Disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8687-1178</contrib-id><name><surname>Svoboda</surname><given-names>Steven A.</given-names></name><email>ssvoboda@vt.edu</email><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eikenberg</surname><given-names>Joshua D.</given-names></name><email>jdeikenberg@carilionclinic.org</email><xref ref-type="aff" rid="I2"><sup> 2</sup></xref></contrib><contrib contrib-type="Academic Editor"><name><surname>Cogulu</surname><given-names>Ozgur</given-names></name></contrib></contrib-group><aff id="I1"><sup>1</sup><addr-line>Virginia Tech Carilion School of Medicine</addr-line><addr-line>Roanoke</addr-line><addr-line>VA</addr-line><country>USA</country><ext-link ext-link-type="domain-name">vt.edu</ext-link></aff><aff id="I2"><sup>2</sup><addr-line>Section of Dermatology</addr-line><addr-line>Virginia Tech Carilion School of Medicine</addr-line><addr-line>Roanoke</addr-line><addr-line>VA</addr-line><country>USA</country><ext-link ext-link-type="domain-name">vt.edu</ext-link></aff><pub-date pub-type="publication-year"><year>2020</year></pub-date><pub-date pub-type="archival-date"><day>11</day><month>11</month><year>2020</year></pub-date><volume>2020</volume><history><date date-type="received"><day>11</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2020</year></date><date date-type="pub"><day>11</day><month>11</month><year>2020</year></date></history><permissions><copyright-year>2020</copyright-year><copyright-holder>Copyright © 2020 Steven A. Svoboda and Joshua D. Eikenberg.</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><italic>Nocardia</italic> is an aerobic, Gram-positive, partially acid-fast bacterium that often manifests as pulmonary infection since the primary route of entry is via the respiratory tract. As an opportunistic organism, <italic>Nocardia</italic> primarily affects immunocompromised individuals. Infection with <italic>Nocardia</italic> is uncommon. Primary cutaneous nocardiosis which is caused by percutaneous inoculation is even more rare. Here, we report a case of primary cutaneous nocardiosis in an adolescent with Crohn disease receiving treatment with adalimumab and azathioprine. Early identification and treatment are important to prevent disease progression and to avoid severe complications. Diagnosis is made principally by culture. Given that culture results may take up to two weeks to return, primary cutaneous nocardiosis should be maintained in the differential for any superficial cutaneous infection that arises in individuals undergoing treatment with immunosuppressive agents.</p></abstract><counts><fig-count count="1"/><ref-count count="10"/><page-count count="3"/></counts></article-meta></front>